Interim positron emission tomography scan in Hodgkin lymphoma: Definitions, interpretation rules, and clinical validation

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1761-1764

  Gallamini, Andrea ^a   Fiore, Francesca ^a   Sorasio, Roberto ^b   Meignan, Michel ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Hodgkin lymphoma; Interpretation rules; PET scan

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER SURVIVAL; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 71049133932     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903308072     Document Type: Conference Paper

References (25)

1. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002;13:75-78.
2. Brusamolino E, Baio A, Orlandi E. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006;12: 6487-6493.
3. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-7564.
4. Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21: 3440-3446.
5. Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin's disease. Cancer 2001;91:1467-1478.
6. Hasenclever D, Diehl V; for the International Prognostic Factors Project on advanced Hodgkin's disease. A prognostic score to predict tumor control in advanced Hodgkin's disease. N Engl J Med 1998;339:1506-1514.
7. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 2008;20:206-219.
8. Hutchings M, Barrington SF. PET/CT for therapy response assessment in Lymphoma. J Nucl Med 2009;50:21S-30S.
9. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 2009;27:1906-1914.
10. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752.
11. Gallamini A, Rambaldi A, Patti C, et al. BEACOPP chemotherapy is able to induce durable complete remission in poorprognosis Hodgkin's lymphoma patients with a positive interim PET after 2 ABVD cycles. Blood 2008;112:2594.
12. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression- free survival inHodgkin lymphoma.Blood 2006;107:52-59.
13. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.
14. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988;6:931-933.
15. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297.
16. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008;111:2339-2346.
17. MacManus MP, Seymour J, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 2007;7:10-18.
18. Kostakoglu L. Early prediction of response to therapy: The clinical implications in Hodgkin's and non-Hodgkin's lymphoma. Eur J Nucl MedMol Imaging 2008;35:1413-1420.
19. Gallamini A. The prognostic role of positron emission tomography scan in Hodgkin's lymphoma. Haematologica 2009;3:144-150.
20. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol
21. Spaepen K, Stroobants S, Dupont P, et al. [18F]FDG PET monitoring of tumour response to chemotherapy: Does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688.
22. Barrington SF, Quian W, Somer EJ, et al. Concordancey between four European Centres reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2009;36(Suppl. 2):S252.
23. Gallamini A, Hutchings M, Avigdor A, et al. Early interim PET scan in Hodgkin lymphoma: Where do we stand? Leuk Lymphoma 2008;49:659-662.
24. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009;Jun 17:1-4 [Epub ahead of print].
25. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009;27:2739-2741. 1750-1752